Role of β blockers in congestive heart failure

Congestive Heart Failure

Volumn 6, Issue 6, 2000, Pages 299-312

  Khan, N U A ^a   Movahed, A ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CANDESARTAN; CAPTOPRIL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; METOPROLOL; NEBIVOLOL; NEUROHORMONE; PROPRANOLOL;

ADRENERGIC SYSTEM; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; HUMAN; META ANALYSIS; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURVIVAL; SYMPTOMATOLOGY;

EID: 0034426755     PISSN: 10797998     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (129)

1. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with or without congestive heart failure: A substudy of the studies of left ventricular dysfunction (SOLVD)
2. Norepinephrine spillover to plasma in patients with congestive heart failure: Evidence of increased overall and cardiorenal sympathetic nervous activity
3. Remodeling and reparation of the cardiovascular system
4. Antidiuretic hormone in congestive heart failure
5. Increased plasma arginine vasopressin levels in patients with congestive heart failure
6. The relationship of the sympathetic nervous system and the renin-angiotensin-aldosterone system in congestive heart failure
7. Potential role of the tissue renin-angiotensin system in the pathophysiology of congestive heart failure
8. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to the hemodynamic abnormality in congestive heart failure
9. Plasma catecholamine levels in patients with congestive heart failure
10. Neurohormonal activation in congestive heart failure
11. Relationship of renin-angiotensin-aldosterone system to clinical status in heart failure
12. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure
13. Role of neurohormonal mechanisms in determining survival in patients with severe chronic heart failure
14. Mechanism of action of beta-blocking agents in heart failure
15. The effects of norepmephrine on myocardial biology, implications for the therapy of heart failure
16. Pathological hypertrophy and cardiac interstitium: Fibrosis and renin-angiotensin-aldosterone system
17. Remodeling of the rat right and left ventricles in experimental hypertension
18. Role of mechanical and hormonal factors in cardiac remodeling and the biologic limits of myocardial adaptation
19. Induction of tumor supression gene p53 in cardiac tissue may be mediated by angiotensin II
20. The cellular basis of dilated cardiomyopathy in humans
21. Wall stress and patterns of hypertrophy in the human left ventricle
22. Neurohormonal activation in preclinical heart failure: Remodeling and the potential for intervention
23. Adrenergic effects on the biology of the adult mammalian cardiocyte
24. Angiotensin II (AII) induced myocyte necrosis: Role of the AII receptor
25. Sarcoplasmin reticulum gene expression in cardiac hypertrophy and heart failure
26. Differences in cardiac calcium release channels (ryanodine receptor) in myocardium from patients with end-stage heart failure caused by ischemic versus dilated cardiomyopathy
27. Adverse consequences of high sympathetic nervous activity in the failing human heart
28. Accumulation of collagen in the cardiac interstitium of dogs with chronic heart failure is associated with decreased capillary density and increased oxygen diffusion distance
29. Accumulation of interstitial collagen in the failing left ventricular myocardium is associated with increased anaerobic metabolism among affected cardiomyocytes
30. Cardiac myocyte necrosis induced by angiotensin II
31. Apoptosis in myocytes in end-stage heart failure
32. Apoptosis in the failing human heart
33. Stretch-induced programmed myocyte cell death
34. Stretch-mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the Bcl-2-to Bax protein ratio in the cell
35. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes: Involvement of the sphingolipid signaling cascade in the cardiac cell death
36. Norepinephrine stimulates apoptosis in the adult rat ventricular myocytes by activation of the β adrenergic pathway
37. Differential gene expression of extracellular matrix components in dilated cardiomyopathy
38. Atrial natriuretic peptide in heart failure
39. Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure
40. Neurohormonal prediction of benefit from carvedilol in ischemic left ventricular dysfunction
41. Baroreceptor function in congestive heart failure: Effect on neurohormonal activation and regional vascular resistance
42. Neural regulation of sympathetic nervous activity in heart failure
43. Clinical aspects of sympathetic activation and parasympathetic withdrawal in heart failure
44. Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure
45. Circadian patterns of heart rate variability in heart failure is progressively disturbed with increasing neurohormonal activation
46. Decreased heart rate variability and its association with increased mortality after myocardial infarction
47. Heart rate variability in idiopathic dilated cardiomyopathy: Relation to disease severity and prognosis
48. Depressed heart rate variability as an independent predictor of death in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy
49. Effect of long term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction: Results of SOLVD echocardiography substudy
50. Effects of enalapril on mortality in severe congestive heart failure: Results of the cooperative North Scandinavian enalapril survival study
51. Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent and selective β1-adrenergic antagonist
52. Cardiac adrenergic receptor effects of carvedilol
53. Actions of dilevalol on adrenoreceptors
54. Pharmacology of bucindolol in isolated canine smooth muscle
55. Mechanism of action of bucindolol in human ventricular myocardium
56. Nebivolol dilates human forearm vasculature. Evidence for an L-arginine/NO-dependent mechanism
57. The role of third generation beta-blocking agents in chronic heart failure
58. Carvedilol, a new vasodilator and beta-adrenergic antagonist, is an antioxident and free radical scavenger
59. Early reduction of neurohormonal factors play a key role in mediating the efficiency of beta-blocker therapy for congestive heart failure
60. Comparative hemodynamics, left ventricular functional and anti adrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart
61. Effects of bucindolol on neuroharmonal activation in chronic heart failure
62. Long term carvedilol therapy increases parasympathetic nervous system activity in chronic congestive heart failure
63. Prognostic value of bisoprolol induced hemodynamic effects in during cardiac insufficiency bisoprolol study (CIBIS)
64. The effects of metoprolol and captopril on heart rate variability in patients with idiopathic dilated cardiomyopathy
65. Change in endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure
66. Plasma big endothelin-1 concentrations in congestive heart failure patients with or without systemic hypertension
67. Evidence for endothelin-1 mediated vasoconstriction in severe chronic heart failure
68. Beta-adrenergic pathways in the non failing and failing human ventricular myocardium
69. Increased beta receptor density and improved hemodynamic response to catecholamine stimulation during long term metoprolol therapy in heart failure from dilated cardiomyopathy
70. Functional b3-adrenergic receptor in human heart
71. The negative inotropic effect of b3-adrenoreceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle
72. Carvedilol, a new beta adrenoreceptor blocker and free radical scavenger, attenuates myocardial ischemia-reperfusion injury in hypercholestrolemic rabbits
73. Cardioprotective effects of carvedilol, a novel beta adrenoreceptor antagonist with vasodilating properties, in anesthetized minipigs: Comparison with propranolol
74. Carvedilol, a novel vasodilating beta adrenoreceptor antagonist, prevents low-density lipoprotein (LDL)-enhanced leucocyte adhesion to endothelial cells by inhibition of LDL oxidation
75. Carvedilol, a new vasodilating beta-adrenoreceptor blocker, inhibits oxidation of low density lipoproteins by vascular smooth muscle cells and prevents leucocyte adhesion to smooth muscle cells
76. Carvedilol, a new vasodilating beta-adrenoreceptor blocker antihypertensive drug, protects endothelial cells from damage initiated by xanthine-xanthine oxidase and neutrophils
77. Carvedilol, a new hypertensive agent, prevents lipid peroxidation and oxidative injury to endothelial cells
78. Normal and abnormal consequences of apoptosis in the human heart: From postnatal morphogenesis to paroxysmal arrhythmias
79. Protective effects of carvedilol in the myocardium
80. Myocardial protection by the novel vasodilating beta-blocker, carvedilol: Potential relevance of antioxidant activity
81. Free radical activity increases with NYHA class in congestive heart failure
82. Prospective randomized comparison of effects of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure
83. Late effects of acute infarction dilation on heart size, a two dimensional echocardiography study
84. Ventricular remodeling: Consequences and therapy
85. Structural basis of heart failure, ventricular remodeling and its pharmacological inhibition
86. Medical therapy can improve the biologic properties of the chronically failing heart: A new era in the treatment of heart failure
87. Time course of improvement of left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockage
88. Carvedilol is associated with reversal of remodeling in chronic heart failure
89. Effects of carvedilol on left ventricular mass, chamber geometry and mitral regurgitation in chronic heart failure
90. Carvedilol prevents remodeling in patients with left ventricular dysfunction after acute myocardial infarction
91. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease
92. Effects of chronic beta adrenergic receptor blockade in congestivie cardiomyopathy
93. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy
94. Effects on metoprolol on myocardial function and energetics in patients with non ischemic cardiomyopathy: A randomized double blind, placebo controlled study
95. Improved exercise hemodynamic status in dilated cardiomyopathy after beta-adrenergic blockage treatment
96. Effects of metoprolol-CR in patients with ischemic and dilated cardiomyopathy, the RESOLVD pilot study (Phase II)
97. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: A randomized trial
98. Effects of beta adrenergic blocking therapy on left ventricular diastolic relaxation properties in patients with dilated cardiomyopathy
99. A randomized trial of beta blockade in heart failure: The cardiac insufficiency bisoprolol study (CIBIS)
100. Randomized, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease
101. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure
102. Double-blind, placebo-controlled study of the long term efficacy of carvedilol in patients with severe heart failure
103. Carvedilol inhibits clinical progression in patients with mild symptomatic heart failure
104. Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure
105. Carvedilol improves left ventricular function and symptoms in chronic heart failure. A double-blind randomized study
106. Effects of short term and long term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy
107. Carvedilol produces dose related improvement in left ventricular function and survival in subjects with chronic heart failure
108. Effects of carvedilol on right ventricular function in chronic heart failure
109. Effects of carvedilol on systolic and diastolic left ventricular performance in idiopathic dilated cardiomyopathy or ischemic cardiomyopathy
110. Long term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol
111. Clinical effects of beta-adrenergic blockade in chronic heart failure. A meta-analysis of double-blind, placebo-controlled, randomized trials
112. Beta blocker therapy for congestive heart failure. A systematic overview and critical appraisal of the published trials
113. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomized intervention trial in heart failure (MERIT-HF)
114. Rationale, design and organization of the metoprolol CR/XL randomized Intervention trial in heart failure (MERIT-HF)
115. Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: Design of the randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study
116. Long term survival effect of metoprolol in dilated cardiomyopathy
117. The cardiac insufficiency bisoprolol study (CIBIS II): A randomized trial
118. The effects of carvedilol on morbidity and mortality in patients with chronic heart failure
119. Effects of beta blockade on mortality in patients with heart failure. Meta-analysis of randomized clinical trials
120. Effects of beta blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials
121. Meta-analysis of randomized clinical trials on beta-blocker treatment in heart failure
122. Effects of beta-adrenergic blockade on survival of patients with chronic heart failure
123. The impact of beta receptor blocker addition to high dose angiotensin converting enzyme inhibitor-nitrate therapy in heart failure
124. More favourable effects from metoprolol than from captopril in patients with dilated cardiomyopathy
125. Practical guidelines for initiation of beta-adrenergic blockade in patients with chronic heart failure
126. Consensus recommendations for the management of chronic heart failure
127. Dose response of chronic beta blocker treatment in heart failure from either dilated or ischemic cardiomyopathy
128. Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure
129. Design of the beta-blocker evaluation of survival trial (BEST)